These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 22538032

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
    Vézina C, Carcao M, Infante-Rivard C, Lillicrap D, Stain AM, Paradis E, Teitel J, Rivard GE, Association of Hemophilia Clinic Directors of Canada and of the Canadian Association of Nurses in Hemophilia Care.
    Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
    [Abstract] [Full Text] [Related]

  • 23. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.
    Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM, European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.
    Thromb Haemost; 2017 Dec; 117(12):2274-2282. PubMed ID: 29212115
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E.
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC, Liao YM, Tsai SP, Chang TT.
    Pediatr Blood Cancer; 2011 Dec 01; 57(6):1029-33. PubMed ID: 21793191
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
    Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J.
    Haemophilia; 2013 Jan 01; 19(1):106-12. PubMed ID: 22762454
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J, Skulimowska J, Windyga J, Lopaciuk S, Kościelak J.
    Arch Immunol Ther Exp (Warsz); 2005 Jan 01; 53(4):352-6. PubMed ID: 16088320
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A.
    Aznar JA, Moret A, Ibáñez F, Vila C, Cabrera N, Mesa E, Bonanad S.
    Haemophilia; 2014 Sep 01; 20(5):624-9. PubMed ID: 24697977
    [Abstract] [Full Text] [Related]

  • 34. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J, Berntorp E, Lindvall K, Björkman S.
    Haemophilia; 2004 Nov 01; 10(6):689-97. PubMed ID: 15569163
    [Abstract] [Full Text] [Related]

  • 35. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar 01; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 36. [Frequency of factor VIII inhibitor in the patients with hemophilia A and environmental risk factors for inhibitor development].
    Yan ZY, Fan LK, Li KX, Wang XY, Hua BL, Wang SJ, Zhao YQ.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct 01; 31(5):580-3. PubMed ID: 19968075
    [Abstract] [Full Text] [Related]

  • 37. [Inhibitor development after changing FVIII/IX products in patients with haemophilia].
    Kocher S, Asmelash G, Makki V, Müller S, Krekeler S, Alesci S, Miesbach W.
    Hamostaseologie; 2012 Oct 01; 32 Suppl 1():S39-42. PubMed ID: 22961330
    [Abstract] [Full Text] [Related]

  • 38. Treatment related factors and inhibitor development in children with severe haemophilia A.
    Maclean PS, Richards M, Williams M, Collins P, Liesner R, Keeling DM, Yee T, Will AM, Young D, Chalmers EA, Paediatric Working Party of UKHCDO.
    Haemophilia; 2011 Mar 01; 17(2):282-7. PubMed ID: 21070501
    [Abstract] [Full Text] [Related]

  • 39. How I treat inhibitors in haemophilia.
    Makris M, Hay CR, Gringeri A, D'Oiron R.
    Haemophilia; 2012 Jul 01; 18 Suppl 4():48-53. PubMed ID: 22726083
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.